International Clinics
Daily
EMA recommends Foundayo (orforglipron), a once-daily GLP-1 tablet for obesity and type 2 diabetes
On 16 October 2026 the EMA's human medicines committee recommended authorising Foundayo (orforglipron) in the EU.